The Company has built a new model for bringing innovative medicines to patients more rapidly and cost effectively," said Belesis.
New York, New York (PRWEB) March 05, 2013
John Thomas Financial an independent broker-dealer and investment banking firm announced back on July 19th of 2011 that the company had raised $40 million to take part in a private-equity deal for Kadmon's biopharmaceutical operations. John Thomas Financial is pleased to announce that it has raised an additional $20 million for the company. These proceeds from the equity placement will support Kadmon Corporation's ongoing operations, and build the Company's diversified research, development and commercial assets.
Proceeds from the equity placement will support Kadmon Corporation's ongoing operations, and build the Company's diversified research, development and commercial assets.
John Thomas Financial CEO Thomas Belesis says he saw an exceptional opportunity with Kadmon, one that highlights John Thomas Financial's core values. "Kadmon is breaking ground in the biopharmaceutical industry and we are proud to have a relationship with a company helping people fight serious disease. The Company has built a new model for bringing innovative medicines to patients more rapidly and cost effectively," said Belesis.
About John Thomas Financial:
John Thomas Financial, a member of FINRA and SIPC, is an independent broker-dealer and investment banking firm headquartered in New York City's Wall Street district. Emphasizing a client-centric approach to managing all aspects of its business, John Thomas Financial and its affiliates offer a full complement of retail brokerage, private wealth management, and corporate advisory services tailored to the unique needs of its clients. The firm publishes the Fiscal Liquidity Index, a unique daily indicator that looks at government spending and its impact on the financial markets, The Kaufman Report, a weekly technical stock market analysis, and The John Thomas Financial Economic Outlook, a report analyzing consumer sentiment, market outlook, credit cycles and dozens of other market influences.
The information provided in this publication is for informational purposes only. Investors should consider this report as only a single factor in making their investment decision. This informational report is not an offer to sell or a solicitation to buy any security. This report has been prepared as a matter of general information. It is not intended to be a complete description of any company, and is not an offer to buy or sell any security. All facts and statistics are from sources believed to be reliable, but are not guaranteed as to accuracy. Before acting on the materials herein you should consider whether it is suitable for you particular circumstances and, if necessary seek professional advice investments involve risk and an investor may incur losses. Past performance is no guarantee of future performance. Trading and investment decisions are the sole responsibility of the reader.